NASDAQ:HSGX - Histogenics Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$8.74
▼ -0.23 (-2.56%)
Get New Histogenics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSGX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Histogenics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $8.74.
N/A
The current consensus among 0 investment analysts is to n/a stock in Histogenics. This rating has held steady since December 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/2/2019HC WainwrightDowngradeHoldHigh
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/24/2018HC WainwrightDowngradeBuy ➝ NeutralN/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/9/2018HC WainwrightSet Price TargetBuy$1.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/6/2018Needham & Company LLCBoost Price TargetBuy$5.00High
i
9/5/2018BTIG ResearchDowngradeBuy ➝ Neutral$3.50High
i
9/5/2018HC WainwrightReiterated RatingBuy$2.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/13/2018HC WainwrightReiterated RatingBuy$3.50High
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/1/2018Brookline Capital ManagementReiterated RatingBuyMedium
i
Rating by K. Raja at Brookline Capital Management
5/11/2018HC WainwrightSet Price TargetBuy$4.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/19/2018HC WainwrightReiterated RatingBuy$4.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/27/2017HC WainwrightSet Price TargetBuy$4.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/21/2017Canaccord GenuityReiterated RatingBuy$4.00Low
i
11/21/2017HC WainwrightReiterated RatingBuy$3.50N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/2/2017HC WainwrightReiterated RatingBuy$3.50N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/11/2017Canaccord GenuityReiterated RatingBuy$4.00Low
i
8/11/2017HC WainwrightSet Price TargetBuy$4.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/13/2017HC WainwrightSet Price TargetBuy$4.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/11/2017Canaccord GenuityReiterated RatingBuyMedium
i
Rating by Kyle Rose at Canaccord Genuity
3/20/2017HC WainwrightSet Price TargetBuy$4.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/23/2017Canaccord GenuitySet Price TargetBuy$5.00N/A
i
Rating by Kyle Rose at Canaccord Genuity
12/19/2016HC WainwrightInitiated CoverageBuy$3.50N/A
i
Rating by S. Ramakanth at HC Wainwright
9/19/2016Needham & Company LLCBoost Price TargetBuy$8.00 ➝ $11.00N/A
i
9/7/2016William BlairDowngradeOutperform ➝ Market PerformN/A
i
8/11/2016BTIG ResearchUpgradeNeutral ➝ Buy$3.50N/A
i
Rating by Sean Lavin at BTIG Research
5/15/2016BTIG ResearchReiterated RatingHoldN/A
i
Rating by Sean Lavin at BTIG Research
5/12/2016Canaccord GenuityReiterated RatingBuyN/A
i
Rating by Kyle Rose at Canaccord Genuity
3/13/2016BTIG ResearchReiterated RatingNeutralN/A
i
(Data available from 3/8/2016 forward)
Histogenics logo
Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $8.74
$7.48
$9.34

50 Day Range

MA: $1.33
$0.16
$3.07

52 Week Range

Now: $8.74
$0.08
$1.43

Volume

33,732,297 shs

Average Volume

9,057,628 shs

Market Capitalization

$826.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.1

Frequently Asked Questions

What sell-side analysts currently cover shares of Histogenics?

The following equities research analysts have issued research reports on Histogenics in the last year:
View the latest analyst ratings for HSGX.

What is the current price target for Histogenics?

0 Wall Street analysts have set twelve-month price targets for Histogenics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Histogenics in the next year.
View the latest price targets for HSGX.

What is the current consensus analyst rating for Histogenics?

Histogenics currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for HSGX.

What other companies compete with Histogenics?

How do I contact Histogenics' investor relations team?

Histogenics' physical mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company's listed phone number is 781-547-7900 and its investor relations email address is [email protected] The official website for Histogenics is www.histogenics.com.